Skip to main content
SpringerLink
Log in

Gemtuzumab ozogamicin cost effective compared with standard of care for AML in the UK

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was affiliated with, and funded by Pfizer.

Reference

  • Russel-Smith TA, et al. Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK PharmacoEconomics-Open : 29 Jun 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00278-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gemtuzumab ozogamicin cost effective compared with standard of care for AML in the UK. PharmacoEcon Outcomes News 882, 13 (2021). https://doi.org/10.1007/s40274-021-7847-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7847-0

Search

Navigation